Opko Health (OPK) EBITDA (2010 - 2026)

Opko Health (OPK) has 17 years of EBITDA data on file, last reported at -$7.0 million in Q2 2026.

• Quarterly EBITDA rose 88.38% year-over-year to -$7.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$48.2 million (up 87.28% YoY) and the FY2025 annual result came in at -$117.4 million, up 22.79% from the prior year.
• EBITDA climbed to -$7.0 million in Q2 2026, from -$51.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $48.1 million in Q3 2025 to a low of -$133.1 million in Q2 2024.
• A 5-year average of -$51.9 million and a median of -$60.0 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA surged 165.42% — and 2024, when it tumbled 1995.27%.
• Tracing OPK's EBITDA over 5 years: stood at -$55.3 million in 2022, then declined by 24.93% to -$69.0 million in 2023, then tumbled by 72.24% to -$118.9 million in 2024, then soared by 67.78% to -$38.3 million in 2025, then surged by 81.8% to -$7.0 million in 2026.
• The last three EBITDA figures came in at -$7.0 million (Q2 2026), -$51.0 million (Q1 2026), and -$38.3 million (Q4 2025), per Business Quant data.